Palatin Technologies, Inc. (AMEX:PTN) is a biopharmaceutical company focused on discovering and developing receptor-specific peptide and small molecule therapeutics, including melanocortin and natriuretic peptide receptor-based therapeutics.

Palatin is developing products targeting melanocortin and natriuretic receptors in the sexual dysfunction, obesity, and cardiovascular fields, including acute hospital care products for use in treatment of acute systemic hypertension, congestive heart failure, and hemorrhagic shock.